Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Research & Development: 2019-2024

Historic Research & Development for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $94.5 million.

  • Foghorn Therapeutics' Research & Development fell 18.98% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.9 million, marking a year-over-year decrease of 14.56%. This contributed to the annual value of $94.5 million for FY2024, which is 13.82% down from last year.
  • Latest data reveals that Foghorn Therapeutics reported Research & Development of $94.5 million as of FY2024, which was down 13.82% from $109.7 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Research & Development registered a high of $109.7 million during FY2023, and its lowest value of $57.7 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $105.6 million (2022), whereas its average is $103.3 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 39.18% in 2021, then decreased by 13.82% in 2024.
  • Foghorn Therapeutics' Research & Development (Yearly) stood at $57.7 million in 2020, then soared by 39.18% to $80.3 million in 2021, then spiked by 31.49% to $105.6 million in 2022, then climbed by 3.85% to $109.7 million in 2023, then dropped by 13.82% to $94.5 million in 2024.